Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
May 13, 2025
Earnings Call Speaker Segments
Jost Reinhard
executiveGood afternoon, everyone, and good morning as well. Welcome to the conference call where we'll be discussing the results of the first quarter of 2025. To get us started, Bill is going to offer his perspective on how the business performed overall and on the progress achieved so far on our strategic priorities. After that, Wolfgang will give more detail on the quarter one financials, the geopolitical situation as it currently stands, and what we expect for the rest of the year. Our Q&A session will follow the presentations, and the presidents of our three divisions will join us for that as well. As a reminder, we'd also like you to join the crop science webinar taking place later today. It begins at 4:00 P.M. Central European Time, which is 10:00 A.M. Eastern Time, and there we'll go deeper into the division's strategy and outlook. Before we get going, please take note of the cautionary language contained in our safe harbor statement. With that, Bill, over to you.
Bill Anderson
executiveThanks, Jost. Yeah, hi everybody. Appreciate you being on the call with us today. We're eager to walk you through the Q1 results of our business. We also realize that the geopolitical and economic uncertainty right now is front and center. Wolfgang and I will attempt to convey how we're thinking about that too. Let's begin with how we performed in the first quarter. First, a reminder that when we discuss sales growth, it's on a currency- and portfolio-adjusted basis. At the group level, sales are flat versus a year ago, which puts us comfortably inside the -3% to +1% corridor we guided for 2025. Core EPS was EUR 2.49, and we remain on track to hit our outlook of EUR 4.50-EUR 5.00 at constant currencies. Free cash flow stands at EUR -1.5 billion. As we've said previously, that negative number reflects the seasonal pattern of the crop business. It's also EUR 1 billion better than the same point a year ago. We're on pace to finish within our 2025 guidance. Now I'll take you through each of our businesses. Back in March, we indicated that we anticipated mid-single digit sales declines for crop science in Q1.
Bill Anderson
executiveSales fell 3%. As we anticipated, regulatory effects took a bite out of certain higher-margin sales, and that explains why our EBITDA margin trails last year's Q1 figure. On the whole, we anticipate growth in Q2, and we remain on track to meet our outlook for the year. Within pharmaceuticals, we delivered a robust first quarter, with 4% growth. NUBEQA and KERENDIA kept up their outstanding momentum. Combined, they were up 80% versus a year ago. Those gains more than made up for the reductions we're experiencing on Xarelto. I'd also like to highlight our cost discipline in pharma. With launch activities running throughout the business, 12% earnings growth is a remarkable achievement and an encouraging signal that our model is helping teams accomplish more with fewer resources. We recognize that the Xarelto declines will weigh heavily on both our top and bottom line for the rest of the year, yet we're just as confident in the momentum of our launches and the fundamentals of our business. In fact, in a more certain environment, we would probably have raised our guidance for pharmaceuticals. With the uncertainty surrounding tariffs, we believe it's prudent to reaffirm what we stated in March and then watch developments closely. Based on what we see at present, we expect our pharma business to land at the upper end of our 2025 outlook on both the top and bottom line.
Bill Anderson
executiveIn Consumer Health, we achieved 2.5% growth, with contributions coming from across the business, even as we faced soft conditions in key markets. Most importantly, we delivered 2% volume growth in Q1. On margins, we were slightly behind prior year, but our guidance of 23%-24% is well within reach. Overall, these results put us in a good position to deliver the year. Now on to our strategic priorities. You see them captured on the slide. I'll touch on select highlights here. On the pharma pipeline, the Beyonttra launch is underway in the EU, and we're prepping to launch elinzanetant in the second half of the year. On litigation, we received an adverse decision by the Superior Court of Pennsylvania, an appeal court, last week. That led to a technical revision of the provision, while we will continue to appeal. This also underscores the need of the US Supreme Court to provide clarity on federal pre-emption. Our multi-pronged strategy to significantly contain litigation proceeds apace. We filed for US Supreme Court review in the Darnell case, and we've received notable amicus briefs in support of the argument from legal scholars, commodity groups, and other experts in support of the merits of our petition. We also filed two hold petitions with SCOTUS for the Johnson and Salas cases as the issue of federal pre-emption exists for both, as in Darnell, and we seek the court to hold cases pending final resolution of the Darnell case.
Bill Anderson
executiveWhen it comes to legislation, we're encouraged by what's happening in a number of states — North Dakota has passed its bill, and in Georgia the governor signed this important piece of legislation just last Friday. We're watching for further movement in other key states as their legislative sessions wrap up over the weeks and months ahead. Turning to crop science profitability, our team is acting to strengthen midterm performance. Yesterday we shared some changes affecting our production and R&D network in Germany. Those calls are hard to make. We don't take them lightly, yet they're needed so the business is positioned for what lies ahead. Later today, Rodrigo and his team will give you more detail on how we're preparing the business to deliver gains in growth, profit, and cash across a five-year horizon. Last, our new system. At Bayer, people are pushing forward on the journey to make the company leaner, faster, and more productive. We cut around 2,000 roles during the first quarter of 2025, which brings the total reduction to roughly 11,000 roles since the system launched in July of 2023. Right now we're concentrating on two major enablers. The first is freeing up resources so teams can move toward the highest-impact work. The second is putting in place people enablement tools suited to our new system and that keep helping us attract and retain top talent.
Bill Anderson
executiveThree points to wrap up with. To start, even with the challenges coming from patent expirations and regulatory effects, the opening quarter leaves us well positioned to deliver during what is a demanding and significant year for the company. Next, we have a plan in place to tackle the company's most important priorities. Later today you'll get a chance to hear more detail on one of those, crop science profitability. And last, our mission is to deliver health and nutrition solutions no matter what comes our way. We're watching the macro environment closely and will adjust as needed. Wolfgang, over to you.
Wolfgang Nickl
executiveThank you, Bill. And hello from me as well. I'd like to begin by giving a bit more detail on what drove our first quarter results. At the group level, Q1 net sales were flat compared with the same quarter a year earlier — on a currency- and portfolio-adjusted basis as well as reported. A drop in crop science was balanced out by gains in both pharmaceuticals and consumer health. EBITDA before special items reached EUR 4.1 billion, which is 7%, or roughly EUR 300 million, under the prior year quarter. That decrease is mostly tied to weaker crop science earnings and a lower reconciliation result. The reconciliation figure was pushed down by higher long-term incentive provisions and balance sheet-related hyperinflation postings. In Q1, the FX headwind on EBITDA before special items amounted to EUR 165 million, driven largely by the hyperinflation effects just mentioned. Core earnings per share came to EUR 2.49, 33% or 12% below the prior year quarter, chiefly due to the lower EBITDA before special items. During Q1, we booked EBITDA-relevant special items of EUR 587 million, which include the update to the glyphosate litigation-related provision that Bill mentioned earlier. As a result, we now anticipate landing closer to the EUR -1.5 billion end of the full-year modeling range we provided.
Wolfgang Nickl
executiveBecause of how seasonal the crop business is, free cash flow was negative EUR 1.5 billion in the first quarter. That's roughly EUR 1 billion better than a year ago, mainly from effects tied to advance payments from our crop science customers, and it includes a factoring change. Consistent with the seasonal pattern of our cash flow, net financial debt rose by EUR 1.7 billion to EUR 34.3 billion since year-end 2024. Compared with a year earlier, though, net financial debt fell by roughly EUR 3 billion. Now let's look more closely at how the divisions performed. Whenever I discuss sales growth, I'll be citing figures adjusted for currency and portfolio as well. At crop science, first-quarter net sales were EUR 7.6 billion, a decline of 3% from the prior year. As a reminder, we had expected mid-single digit decreases in the first quarter, so we're broadly aligned with our internal assumptions. The core business was down 3%, and seeds and traits fell 5%, hurt by weaker soybean and cotton sales stemming from the U.S. dicamba label vacatur, along with corn volume phasing into the second quarter after a strategic adjustment of our distribution network.
Wolfgang Nickl
executiveIn crop protection, our core business rose 2%, helped by increased volumes of non-glyphosate herbicides and partly held back by reduced insecticide volumes in the EU stemming from the Movento registration lapsing. For dicamba and Movento, the Q1 regulatory hit matches what we previously communicated — a 200 to 300 basis points margin impact across the full year. We anticipate that most of this effect will land in the first half. Glyphosate sales fell 10%, reflecting phasing into later quarters to support just-in-time purchases in the southern hemisphere. Turning to profitability, EBITDA before special items was 10% lower at EUR 2.6 billion, giving a margin of 33.7%. That lower margin, as expected, stems mainly from losing high-margin sales because of the regulatory impacts and the corn phasing into Q2. Cost savings allowed us to partly offset these effects. Now let's turn to our pharma business. First-quarter net sales of EUR 4.5 billion rose 4%, with growth across the portfolio more than offsetting the anticipated Xarelto decline. Our launch assets, NUBEQA and KERENDIA, kept performing especially well, with 80% year-over-year growth and combined sales reaching EUR 680 million.
Wolfgang Nickl
executiveThe main force behind this was solid input from the United States. EYLEA posted a healthy 5% gain, helped along by the continued launch of 8 milligram, and performance was especially robust in Europe and Japan as well. Growth of 6% came through in our base business, powered by meaningful contributions out of radiology and women's health, plus robust demand in China for Cardioaspirin and Adalat. Xarelto, as we had anticipated, was down in Q1, finishing 31% under the previous year. Generic competition that keeps persisting in Europe and Japan was the principal cause. Looking at the bottom line, EBITDA before special items rose 12% to EUR 1.3 billion for the first quarter, giving us a 29.5% margin. Greater sales together with ongoing efficiency improvements outweighed both somewhat heavier R&D spending and a 1% FX headwind. Lastly, on consumer health, sales advanced by almost 3%, with growth balanced across categories and regions. Volume added 2%, and pricing added another 1%. Every region did well, with gains across North America, APAC, and EMEA. We stayed flat in LATAM, where consumer sentiment has been subdued amid the U.S.-Mexico trade relationship. Digestive health climbed 13%, lifted by launches and better supply for items such as Iberogast.
Wolfgang Nickl
executiveIn pain and cardio, we posted 7% growth, driven by launches of new products and solid consumption of Saridon in Asia-Pacific. Aspirin likewise delivered a strong performance across every region. Dermatology rose 2% in the quarter, helped by Bepanthen and Canesten, plus innovations in our portfolio such as KangWang in China. The allergy and cold category was up 2%, with strong growth for cold products in North America, partly offset by a slow start to the allergy season. Lastly, nutritional fell 5% year over year, reflecting weak demand for our prenatal nutrition supplements in China and the discontinuation of the care-of business in the U.S. in June of last year. EBITDA before special items rose to EUR 342 million, giving a margin of 22.8%, a touch below prior year but within reach of our guidance range. The gain in EBITDA before special items came mainly from higher sales. In addition, our continued cost management efforts lifted profitability, including a reduction in COGS. That was partly offset by lower divestment income and greater investments in marketing our innovative products. Let's turn now to the outlook. Given the high volatility in the geopolitical environment, I will also share our thinking on the potential direct and indirect impacts around tariffs as well as FX.
Wolfgang Nickl
executiveWe keep a close watch on all the tariff announcements. Our specialists are evaluating what effects these might have and are developing potential fixes so that supply to our customers stays secure. Our priority is keeping supply chains stable and reducing any possible fallout. Given where tariff announcements stand right now and the mitigation steps we have in place, we anticipate being able to handle the impact, and we reaffirm our outlook at constant currencies for the full year 2025. In crop science, we anticipate direct tariff effects will be limited on the whole, with the main hit falling on the crop protection portfolio, since seeds and traits are largely made in the regions where they are sold. At present, the majority of our crop protection active ingredients, along with glyphosate, are exempt from the most recent tariffs. We are additionally assessing indirect business implications. Among other things, these might include the size of acreage shifts from soy to corn in the United States, possible shifts to LATAM in soy, and various pricing and volume scenarios for glyphosate and the wider crop protection portfolio. For the full year in crop science, we are adopting decisive measures to keep sales and margins stable despite considerable regulatory headwinds. As the expected regulatory impact takes effect, recovery in Latin America and crop protection, together with strong efficiency gains, will help offset it so we can reach our full-year guidance.
Wolfgang Nickl
executiveNow turning to pharma. Regarding tariffs, we anticipate some direct impacts on portions of our portfolio, primarily product flows between the U.S. and China. Given our production footprint in the EU, there's a further risk of possible tariffs on pharmaceutical imports entering the U.S. from the EU. As you're aware, those are exempt at present, though subject to a Section 232 investigation. First-quarter business performance, especially for our launch assets, gives us confidence in our capacity to sustainably offset the Xarelto generalization. Taking that into account, along with what we know today about tariffs, we anticipate pharma will deliver at the upper end of our sales and profitability guidance range. For consumer health, our expectations regarding phasing across the year align with the full-year guidance. On the basis of the current tariff announcement, we believe we can manage the direct impacts within the guidance range. We are watching further indirect risks, chiefly tied to possible demand effects arising from weaker consumer confidence. Let me finish with a few remarks on foreign exchange rates too. Over recent weeks, we've observed a material depreciation of the U.S. dollar and other currencies versus the euro, which weighs on our top line and, to a lesser degree, our bottom line.
Wolfgang Nickl
executiveConsistent with our established approach and legal obligations, we're refreshing the FX estimate using spot rates as of the end of March. Relative to constant currencies, that produces the figures you'll find in the final column of the table on page 11 of the investor deck. That said, everyone is aware that currency markets have shifted significantly following the announcements made by the U.S. administration in early April. To give a sense of the possible effect, we ran additional analysis using the spot rates from April 24. Under that scenario, an incremental FX headwind of roughly EUR 900 million in net sales and about EUR 0.10 in core EPS would arise. Conversely, net financial debt would come down by a further EUR 500 million relative to the numbers presented on the slide. We'll keep watching how things develop and will bring you up to date on the impact in our next reporting. With that, I'll end my comments and turn things over to you, Jost, to moderate the Q&A, please.
Jost Reinhard
executiveThanks, Wolfgang. Thanks, Bill. We’re going to begin the Q&A portion now. Stefan and Julio are also here with us in the room for that, and Rodrigo is joining by phone from the United States. Before we begin, the usual few housekeeping notes. If you’d like to ask something, please raise your hand and then follow the instructions given in the chat. So that as many participants as possible can take part, please keep yourself to two questions. First two participants in the line are Richard Vosser from J.P. Morgan and Sachin Jain from Bank of America. Richard, please go ahead.
Richard Vosser
analystI hope you're able to hear me. Thank you for taking my questions. I have two, please. First, regarding crop, you may have mentioned growth in crop during Q2. Could you discuss what benefit came from the shift out of Q1 and what that is contributing in terms of growth? Then, have you observed any effect from forward purchasing, perhaps on crop protection products, given the uncertainty, particularly surrounding the other herbicides, and how do you expect that strength to carry on, if at all, over the coming quarters? My second question is just on EYLEA in pharma. Future expectations, obviously a very strong Q1. Could you give us more color on how the eight milligram is performing and how you see the launch of biosimilars unfolding in the future? Thanks very much.
Bill Anderson
executiveOkay. Rodrigo will handle the first question, and after that Stefan can cover EYLEA.
Rodrigo Santos
executiveAbsolutely. I appreciate the question. I’ll take a closer look at how the core business performed. Excluding the regulatory effect we faced in Q1, the core business would have grown 2.4%. There were only a few specific questions regarding the phasing on corn, and that relates to the accounting treatment we’re applying because of certain changes we made in the U.S. go-to-market approach; under that treatment, our corn business would have grown 2.5% in this first quarter. That is essentially the adjustment we’re making on the accounting side that you’re seeing there. Turning to crop protection, we reported 2% growth in Q1, again affected by Movento. Excluding Movento, we would have grown by 5%. On volume, to address your question, it was 7% higher in Q1. There’s a bit of the dynamic you mentioned regarding the market and some elements shifting from Q1 into Q2. That’s why, when we look at the Q1 numbers, we see them as very consistent with what we had expected; we are reaffirming our guidance for the year and also our confidence in core business growth driven by innovation. That provides a good confirmation of the health of the core business when we examine the performance figures here more closely.
Rodrigo Santos
executiveAppreciate you asking that.
Stefan Oelrich
executiveHi, Richard. Appreciate the question on EYLEA. Yes, we're quite happy with how the first quarter went. What's evident is that in a field that keeps getting more competitive, we're holding share — and in certain geographies even growing it — after the launch of the eight milligrams. We feel very good about that. That said, at this point we're basically bringing in new patients. We aren't yet seeing any shift from two to eight. It's largely new patients. That should pick up once biosimilars come into play. We'll likely see more of a move from two to eight then. Up to that point, we had guided that EYLEA should stay north of EUR 3 billion over the years ahead. That remains our target as of now. Thank you.
Jost Reinhard
executiveThanks, both. Next up we have Sachin Jain from Bank of America. Sachin, the floor is yours.
Sachin Jain
analystHello. Am I coming through okay? Apologies for running late.
Jost Reinhard
executiveYes, you're coming through loud and clear.
Sachin Jain
analystYeah, perfect. Two questions, please, about upcoming events. First, our guess would focus on glyphosate. You mentioned the SCOTUS application introduction.
Jost Reinhard
executiveAnything on timing for when we might hear whether the case is taken up for review? And could you expand on what plan B looks like if SCOTUS doesn't accept it? You mentioned state legislation, but any detail on what comes after that — especially when you'd be able to give us visibility into the structural solutions you've been discussing. Second one, Stefan, I'm sure you know I'm going to ask about asundexian and the phase three data expected toward year-end. Just touch on two things for me. First, what you learned in phase two and carried into phase three about the population you're evaluating and the endpoints. And maybe touch on the market size, since historically the focus for this class has mostly been AF. Thank you.
Bill Anderson
executiveYes, thank you. Thank you, Sachin. Regarding SCOTUS, we believe there are essentially two windows when we might get word. One is in June. That's when we'd hear back on whether they accept our petition or not. It might come in June, or it might come in October or a bit after that. Those are roughly the timelines for when it ought to take place. We believe the filing went in early enough that it could land in that first window. Yeah, difficult to predict. As for a plan B — if what you're asking is, well, what do we do in the event the Supreme Court doesn't accept or something along those lines? Yeah, we certainly aren't putting all our eggs in one basket. I think among the other options available to us, we're collaborating with members of Congress from both the Republicans and the Democrats. This is a bipartisan matter. It ought to be a bipartisan matter. We were glad to see that in Georgia, we had bipartisan legislation. We're working with members of Congress from both parties on that. Language of this kind should also be included in the next farm bill. The question there is, when will the next farm bill be?
Bill Anderson
executiveI mean, one of them was expected last year. Another is kind of running late this year. Given how things stand in Washington right now, it's hard to predict whether that will really come through this year. That would be quite helpful, since federal legislation would be more effective than getting it state by state. We're continuing to push for legislation in other states as well. I suppose that's part of a backup plan. A settlement is always a possibility, because in most cases these kinds of situations do end up being settled. Of course, for us any settlement would have to carry a strong element of finality, and clearly that wasn't achieved with the one that was tried a few years back. Our bar for that would be very high. Lastly, there are some structural options we're getting ready. We need to ensure that, one way or another, we have a means of putting the litigation situation behind us. We believe the Bayer employees, the shareholders, and our customers deserve that. We're putting a lot of effort into it. Maybe Stefan on asundexian?
Stefan Oelrich
executiveOkay. Hi, Sachin. Yeah, I had a feeling your question was coming. First off, thanks for staying interested in the asundexian program. We're really looking forward to the study readout in the second half. Yes, we built our phase three population around those areas, or those populations, where the phase two showed the strongest effect. There's a subgroup looking at the composite of asymptomatic — sorry, recurrent symptomatic ischemic stroke and TIA — and there we saw a 36% risk reduction. That's basically how we've designed phase three, so that this population makes up most of the patients. We're also accounting for a greater likelihood of events when patients come in with atherosclerotic cases. That's factored in too, given how we picked the patient population. On your question about potential, there's no simple answer, because when you look at how the studies are structured, we're currently studying acute cases. Including the prevalent cases would substantially expand the market potential. I think you probably need to view this in two steps. Thank you.
Jost Reinhard
executiveThanks, Stefan. All right. Next up we have James Quigley from Goldman Sachs and Jo Walton from UBS. James, it's your turn.
James Quigley
analystThank you. Yes, I hope you're able to hear me. James Quigley here from Goldman Sachs. I have two questions, please, and two last ones. First, a follow-up regarding asundexian. I believe during the roadshow and on the call last time, last quarter, you appeared confident about efficacy. Given that this trial also includes a safety primary endpoint in terms of time to first major bleeding events, how confident are you about this, considering the data we've seen previously, particularly from the Oceanic AF trial, which, again, I'm aware hasn't been presented externally? Could you confirm whether that is a superiority endpoint or a non-inferiority endpoint on the bleeding side? Second, regarding the phasing on the pharma margin, you obviously had a very strong first quarter. The margin was well above the top end of the guidance range. You've already indicated that you're going to come in for the full year toward the top end. Could you speak to the phasing through the year? Could you quantify how much of the sales beat came from one-off elements in the quarter? I think stocking in aspirin was called out. How should we think about the trajectory for the rest of the year in pharma, given that as well?
James Quigley
analystThank you.
Stefan Oelrich
executiveThanks. Regarding asundexian, I'll need to follow up with you on that—I believe it's non-inferiority on bleeding, though it might be superiority. I'm referring to bleeding. I'm not certain. It's worse than placebo, correct? In stroke? Yes, but he was asking about the entire Oceanic trial, which includes the one that failed. What I can say is that in the Pacific program, we clearly achieved the difference in bleeding that we were looking for. From what I remember, that's also the case in Oceanic, but we'll follow up with you on that, James. It's definitely a good data point. I recall—and I don't have this at the top of my mind—that on the bleeding side, we had a pretty clean bill of health across all the studies we've conducted since phase two, including the first phase three in Oceanic. For the ongoing one, we'll have to see. On the strong first quarter, thank you. I agree. We had an incredibly strong first quarter. That was against the backdrop of Xarelto being at -31%. However, we've also said that we expect the first half to be somewhat stronger than the second half. I think that remains true.
Stefan Oelrich
executiveTo gradually reach a point above a billion—so somewhere in the range we mentioned, EUR 1.2 billion to 1.5 billion. One to 1.5. With Xarelto, we'd need to see the losses pick up somewhat in the second half. The first half was genuinely strong. The one item that fell outside what we'd typically observe was cardioaspirin sales ahead of volume-based procurement in China. Keep in mind that we were up against a comparatively weak quarter a year ago. For the rest of the year, we'll be facing stronger quarters by comparison. Overall, we're very pleased, naturally, with NUBEQA and KERENDIA, each growing at 80% and 90%.
Jost Reinhard
executiveWe're also happy about the sustained robust expansion we're seeing in radiology. In women's health, we're seeing recovery, and I still put that down to some kind of rebound from COVID, which ties back to those long-acting contraceptives that, apparently, need a bit more time to bounce back. Thank you. Thank you. Up next is Jo Walton from UBS. Jo, go ahead, please. Jo, are you able to hear us?
Jo Walton
analystYes.
Jost Reinhard
executiveThanks.
Jo Walton
analystMy apologies. Sorry about that. Is this coming through okay?
Jost Reinhard
executiveYes, you're coming through clearly. Thanks.
Jo Walton
analystOh, thank you. I have one AG question and one pharma question, please. Just on plan B and the state legislature, just to get a sense of the importance of the states where you've been successful. North Dakota, not many people live there. Georgia, you've got a ruling through there, which presumably gets rid of the Barnes case because that was in Georgia. Most relevant, how many of your cases are in Missouri? Can you just tell us a little bit about the timeline for the next steps there? We note that it has passed the lower house as it did last year, but it passed with a smaller majority this time than it did last year. Last year, it failed in the upper house. Can you just give us an idea of the sense of timing and any degree of confidence that you have that you have shifted the mindset there to get that one over the line? My second question would be on elinzanetant. Now, Astellas is not nearly as much of a powerhouse in women's health as you are, but FIOSA really has not done very well. It's sort of fairly stuck now in the last three quarters at between $50 million and $60 million a quarter in the U.S.
Jo Walton
analystCould you give us some sense of how we ought to view that growth, and whether they've managed to do a decent job of at least letting people know something will be available around that, or whether you'll end up stuck with, well, here's another one of those products that isn't especially good. Thank you.
Bill Anderson
executiveYes, thank you, Jo. On the state legislative path, we believe this matters past just the straightforward matter of a state's population count, since in a sense, when you think it through, states ought not to be required to confirm that a federal agency holds authority over something federal law already stated that agency holds authority over. That would be somewhat like a state confirming the FDA has jurisdiction over drug labeling, correct? The reason we find ourselves here, though, is that in our view state courts have misinterpreted the FIFRA statute, essentially concluding that the EPA's mandate lacks authority throughout all 50 states. That's why clarification is needed. Yes, one argument for securing these bills is that it gives manufacturers at least certainty inside those particular states, so at minimum they understand what the rules happen to be. With Missouri, a big majority of life estate lawsuits have been filed there. Now, how does Missouri law apply compared with the law of the state of origin? Take someone in Georgia who files suit in Missouri — are they covered under Georgia law or under Missouri law?
Bill Anderson
executiveA lot of these questions will ultimately have to be settled in the courts as well. The key point is that securing state legislation sends, I believe, a strong message to the U.S. Congress that, hey, states shouldn't be doing your work for you. The law needs to be clarified. Honestly, the Supreme Court is capable of doing that. The U.S. Congress can do it too. State legislatures can help with that as well. Hopefully that gives you a bit more color on it. Do you want to discuss elinzanetant versus FIOSA? Sure.
Stefan Oelrich
executiveHi, Jo, and thank you for your interest in elinzanetant. Maybe just as a preface, we're well on our way, in line with plan, toward getting this product approved around the middle of the year. The U.S. will most likely be our first launch market — in fact, certainly our first launch market. We see a differentiated profile versus other products in the space. We have an NK3, NK1 neurokine inhibitor. We think that also comes through in our clinical results. We have every reason to believe we can be the best product in this class. The unmet need of women who either cannot use hormone therapies, who do not want to take hormone therapies to treat their hot flashes, and also sleep disorder potentially is there. We believe we have a very competitive product. You named it. We're one of the leaders in this space with a strong legacy. We intend to play that. Stay tuned. We still think this has potential north of a billion. This is a blockbuster in our view.
Jost Reinhard
executiveThanks. That’s great.
Jo Walton
analystThanks.
Jost Reinhard
executiveBefore we move on, there's one participant whose hand is raised but we don't know who they are. Just shoot us a brief email so we're able to match it up with the phone number — that would help us a lot. Meanwhile, we'll go next to Christian Feitz at Kepler Cheuvreux, and after that Joel Jackson at BMO. Christian, the floor is yours.
Christian Feitz
analystYes, thank you. Good afternoon, good morning. I have two questions, please. First, regarding crop, the drought right now in Europe appears to be continuing well into May and June. Rodrigo, do you view that as a threat to demand for crop protection products, especially fungicides and insecticides, for Q2? Second, on pharma, I realize that news flow coming out of the U.S. is shifting on at least a daily basis. Still, could you comment on yesterday's White House press conference and what implications it might have for pricing of your pharmaceutical products? Thanks very much.
Bill Anderson
executiveRodrigo. Yeah, my apologies — please go ahead, Rodrigo.
Christian Feitz
analystThanks, Bill.
Rodrigo Santos
executiveChristian, appreciate that. Understood. We’re monitoring things quite closely. The coming weeks across Europe are going to be pivotal, correct? Particularly regarding fungicide application, just as you mentioned. We’ll be keeping a very close eye on it. That’s how it always is, isn’t it? Overall we had a solid season in the Americas. In Europe, several countries are dealing with dryness at the moment. We saw some effect in Turkey’s irrigation area, which is another piece of that impact. We’re tracking that one closely to understand what effect it will have. You hit the nail on the head. The crucial factor is what the weather does over the next weeks and how that affects fungicide. That could have an effect on that. We’ll be monitoring this one. Broadly, looking at things globally, the trend this year is more positive than what we saw last year. That also helps global production overall. Thank you. Back to you, Stefan.
Stefan Oelrich
executiveYeah, thanks for that question, Christian. We're monitoring this every day, just as you are, and it still catches us off guard at times. That said, pricing is a complicated matter, I'd say. Looking at the executive order, the way it's worded makes clear that nobody can offer a definitive answer right now. I think we need to wait a bit and see the details of how this will actually be implemented. With that said, I see it as a clear signal—a call to action—for other regions, Europe in particular, to examine ways to better back innovation through pricing. To me, that's a very explicit request, and it ought to be a chance for Europe to establish itself as a firm champion of this industry—the innovative industry.
Christian Feitz
analystMuch appreciated.
Jost Reinhard
executiveGreat, thanks. Up next is Joel Jackson from BMO. Joel, go ahead. Joel, we’re unable to hear you. Could you unmute your line and then proceed with your questions? All right, what I’d suggest is that we move on to the next two callers in the queue. We’ll return to Joel afterward. Coming up next is Vincent Andrews from Morgan Stanley, followed by Laurent Favre from BNP Paribas. Vincent, please go ahead.
Vincent Andrews
analystThank you. Thank you. Good morning. I was wondering whether, on soybeans specifically, you could help us reconcile how this is flowing through. I see what I believe is a 14% reduction in soybean season traits revenue stemming from what's happening with extend. I also see that the glyphosate — or sorry, the herbicides ex-glyphosate sales are actually up. I would have expected dicamba sales to be down a fair amount. Could you just help us understand how it's flowing through? Within seeds and traits, how much is volume versus price? Why are you doing so well in herbicides ex-glyphosate, even with what should be a pretty big headwind from dicamba sales?
Rodrigo Santos
executiveThanks, Vincent. I’ll add some detail on seeds and traits. When you look at CPA, it has a 6% negative effect on volume and a positive % on price. That figure includes the regulatory impact. As I said earlier, Vincent, just touching briefly on corn: corn has a negative CPA, but the accounting treatment is what drives that. Without it, we’d be at 2.5% growth. On North America specifically, we’d be at 3.5% growth once that accounting element is excluded. Turning back to soybean: soybean, you’re exactly right. What affects us is mostly in Q1, on the regulatory side, and mostly in licensing revenue. I’d say the largest piece of the 14% you mentioned comes from licensing revenue generated by big companies in our business. For CP overall, volume is up 7%, excluding Movento from Nero. That’s also partly a shift versus the prior quarter of last year and versus Q1 of last year. There was probably some market anticipation, as we’ve discussed a fair amount of uncertainty in the market around tariffs and so on.
Rodrigo Santos
executiveThere's some anticipation we're seeing when it comes to volume, and that includes the herbicide market — and the herbicide Dicamba too, where that effect has already hit us. It wasn't a huge volume in Q1. The bigger impact came earlier. On soybean overall, the one item I didn't cover in my remarks is that we're seeing strong momentum with Intacta to Extend in Latin America too. We're looking at growth reaching as much as 20% penetration this year. That should also help what we have going in soybean there. This gives a bit more depth on the figures I laid out, Vincent, on that point. Since I have your question, I also saw some of the notes earlier. We expect — and we're confident — that we'll have a dicamba label for the 2026 season. That's something we're working on with the EPA too. Thanks for the question.
Vincent Andrews
analystAll right, that's where I'll stop. Thanks so much.
Jost Reinhard
executiveGreat. Moving on, we have Laurent Favre of BNP Paribas on the line. Laurent, go ahead.
Laurent Favre
analystThat brings us to the final question. Thanks, Jost. Rodrigo, I have two things for you. First, on seeds: from what you said, it seems your view on corn acreage this year is less optimistic than the USDA's. What's behind that assumption? Is it simply a conservative stance, or could you also be losing share in corn? And linked to that, please remind us how much more profitable a corn acre is versus soy. Any rough per-acre sensitivity would be very helpful. My second question concerns CPC. As raw material deflation begins to set in, can you describe the pricing environment? Do you see room for margin expansion, or should we expect greater pricing pressure, particularly from the generics? Thank you.
Rodrigo Santos
executiveThat's great. I'll start us off. No, we're feeling quite optimistic regarding U.S. corn acreage too. Whether it ends up at 95 million acres, as the USDA figure you mentioned suggests, or at 94 million acres, it's difficult to determine at this point. It's simply the nature of the season we're in. Normally by June, once some of the returns come in, you get a solid estimate. Without question, corn in the U.S. is set for very strong growth. That explains why, looking specifically at our North American figures, if I exclude the accounting treatment—shifting some sales recognition from Q1 into Q2—our U.S. corn business would be showing 3.5% growth by now. Things are trending in the right direction. We also expect Q2 to contribute, corn included, and not just for North America but for other regions as well. We anticipate solid corn development worldwide. That should have the right impact here. Regarding your question on overall CP, we do anticipate competitive pricing pressure over the coming quarters, given the substantial capacity buildup in China.
Rodrigo Santos
executiveThat’s exactly why we’ll be discussing this at length later today during our webinar. We’ll spend a good deal of time on the plans we have in place to grow our margin. Last quarter, we announced a plan to expand our margin by EUR 1 billion. That comes from across the entire value chain. We’ll cover some of the R&D adjustments we’ve made, along with a massive contribution from product supply on the EUR 600 million. Of that, 80% is in crop protection. That supports the margin expansion we’re pursuing. There are also some adjustments underway in the go-to-market and the global function. That contributes massively to the margin expansion we have. We’ll keep monitoring prices. Our work on margin expansion is meant to focus heavily on what we can control. That’s something we’re working on right now. We’ll talk more later today and give you a bit more detail on the plans we have for the next year. That’s a brief overall view here.
Rodrigo Santos
executiveThanks.
Jost Reinhard
executiveGreat, thanks. Before we wrap up the call, since there aren't any further questions in the queue, Stefan, would you like to address the points James raised about non-inferiority?
Stefan Oelrich
executiveYes. James, that allowed us the opportunity to check on it. It was a non-inferiority design, since what we used as the comparator was standard of care, which had shown positive leading outcomes. Excellent. We have a good amount of time remaining this afternoon to discuss crop science. Just a reminder that our event is scheduled for 4:00 P.M. At this point, I'd like to express my thanks for your questions and your interest. That brings our earnings call to a close. I look forward to seeing everyone at our virtual crop science event in under an hour. The materials for it are also available now on our IR website. In the meantime, have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.